Oral versus intravenous fluoropyrimidines for colorectal cancer.

about

Oral versus intravenous fluoropyrimidines for colorectal cancer.

Item

http://www.wikidata.org/entity/Q38650502

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Oral versus intravenous fluoropyrimidines for colorectal cancer.

@en

type

Item

label

Oral versus intravenous fluoropyrimidines for colorectal cancer.

@en

prefLabel

Oral versus intravenous fluoropyrimidines for colorectal cancer.

@en

P1476

Oral versus intravenous fluoropyrimidines for colorectal cancer

@en

P2093

David Lau

http://www.w3.org/2001/XMLSchema#string

Fiona Chionh

http://www.w3.org/2001/XMLSchema#string

Niall Tebbutt

http://www.w3.org/2001/XMLSchema#string

Timothy Price

http://www.w3.org/2001/XMLSchema#string

Yvonne Yeung

http://www.w3.org/2001/XMLSchema#string

P2860

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

Oral versus intravenous fluoropyrimidines for colorectal cancer

Adjuvant Therapy for completely resected Stage II Colon Cancer

What is "quality of evidence" and why is it important to clinicians?

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Meta-analysis in clinical trials

Practical methods for incorporating summary time-to-event data into meta-analysis

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

P304

CD008398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/14651858.CD008398.PUB2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28752564

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

6483122

http://www.w3.org/2001/XMLSchema#string